SCHEMBL7060842

SCHEMBL7060842

COc1ccc(Cl)c(N(C(=O)C(=O)O)c2ccccc2C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 15/20 0.49
PTPN2 P17706 1/20 0.45
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
FABP3 P05413 1/20 0.42
FABP4 P15090 1/20 0.42
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062370 0.80 PTPN1 (0.55) PTPN1PTPN2LMNA
SCHEMBL7061182 0.77 PTPN1 (0.60) PTPN1PTPN2KDM4E
SCHEMBL7059668 0.75 PTPN1 (0.57) PTPN1LMNAKDM4EALDH1A1GLA
SCHEMBL7065042 0.73 PTPN1 (0.64) PTPN1
SCHEMBL4261329 0.72 SMN1; SMN2 (0.59) LMNAKDM4EALDH1A1HPGDFABP3
SCHEMBL7064433 0.71 PTPN1 (0.65) PTPN1
Hydrochloric Acid SCHEMBL18861007 0.71 SMN1; SMN2 (0.57) LMNAKDM4EALDH1A1HPGDFABP3
SCHEMBL8475836 0.70 ALDH1A1 (0.47) PTPN1LMNAKDM4EALDH1A1GLA
SCHEMBL7062331 0.70 PTPN1 (0.60) PTPN1
SCHEMBL28600471 0.70 ALDH1A1 (0.53) PTPN1LMNAKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313696-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2003-05-28 EP claimed
US-20020035137-A1 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors ABBOTT LABORATORIES 2002-03-21 US claimed
WO-2002018323-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2002-03-07 WO claimed
EP-1313696-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2003-05-28 EP disclosed
US-20020035137-A1 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors ABBOTT LABORATORIES 2002-03-21 US disclosed
WO-2002018323-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035137-A1 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors PPM1A, PTPRO, PTP4A1 PTPN1 10/4885PTPN2 29/4885LMNA 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.